The Pre-Heart Failure in Hypertension
Main Article Content
Abstract
The objectives of this study were to detect pre-heart failure based on NT-proBNP in subjects with hypertension and to identify the risk factors for pre-heart failure. Research methods: We conducted a cross -sectional study between August and December 2022. This study was included 526 subjects with hypertension aged from 35- to 64 years, who had no clinical symptoms of heart failure. Cardiovascular risk factors were detected by clinical examinations and laboratory test. Hypertension was defined as systolic BP ≥ 130 mm Hg, diastolic BP ≥ 80 mm Hg, and/or receiving treatment with anti-hypertensive agents. NT-pro BNP determination was performed on an immunoassay analyzer (Getein 1100). An elevated NT-pro BNP was defined as a NT-pro BNP ≥ 125pg/ml. Pre-heart failure was based on elevated NT-pro BNPlevel. Ethical statement Research ethical permission was obtained from the Biomedical Ethics Committee of Mongolian National University of Medical Sciences. Research results: In total, 526 hypertensive subjects s aged 35-64 year enrolled in this study, of which, 243 (46.2%) were men and mean age was 52.5±7.7 years.
The prevalence of pre-heart failure based on NT-pro BNP in women was non-significantly higher than in men(17.3% vs 14.0%, p= 0.297). The prevalence of pre-heart failure increased from 4.0% for men aged 35-44 years to 20.9% for men aged 55-64 years. Based on our logistic regression analysis, the likelihood of elevated NT-pro BNP in hypertensive subjects was independently associated with age(OR 2.18, 95%CI 1.51-3.14) and poor blood pressure control(OR 2.41, 95%CI 1.29-4.50). Conclusion: The present study showed that the overall prevalence of pre-heart failure in hypertensive subjects was 15.8% and increased with age. The poor blood pressure control and ageing were significant risk factors in the development pre-heart failure in subjects with hypertension.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Health indicators 2021. Center for Health Development. Mongolia.
II. Tsolmon Unurjargal, Naranchimeg Sodovsuren. Uncontrolled Hypertension and Non-adherence to medical Therapy in Ulaanbaatar, Mongolia. CAJMS.2015;1(10:75-80.
III. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39:571-88.
IV. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time A systematic review. Eur J Heart Fail. 2016;18(3):242–52. https:// doi. org/ 10. 1002/ ejhf. 483.
V. Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I et al. Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial. JAMA. 2013;310(1):66–74. DOI: 10.1001/jama.2013.7588
VI. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition Eur J Heart Fail. 2021; 23:352–380. doi: 10.1002/ejhf.2115.
VII. ] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J. 2021; 42:3599–3726. doi: 10.1093/eurheartj/ehab368.
VIII. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: A scientific statement from the American Heart Association. Circulation. 2016; 134: e535– e578.
IX. National Institute for Health Care and Excellence. Chronic heart failure in adults: Diagnosis and management. 2018. Available at: https:// www. nice. org. uk/ guida nce/ ng106/ resou rces/ chron ic- heart- failu re- in- adults- diagn osis- and- manag ement- pdf- 66141 54131 1685. Accessed February 2020.
X. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https:// doi. org/ 10. 1093/ eurhe artj/ ehw128.
XI. Gori M, Lam CS, D’Elia E, Iorio AM, Calabrese A, Canova P, et al. Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. Eur J Prev Cardiol. 2020;28(9):937–945. https:// doi. org/ 10. 1177/ 20474 87319 899618.
XII. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J. 2008;38(2):101–13. https:// doi. org/ 10. 1111/j. 1445- 5994. 2007. 01454.x
XIII. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52. https:// doi. org/ 10. 1161/ CIR. 0b013 e3182 9e8807.
XIV. Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y, Yoshimasa Y. Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: The Suita Study. Endocr J. 2010; 57:727–33.
XV. Aurore Bergamasco, Anouk Luyet‑Déruaz, Nicholas D. Gollop, Yola Moride, Qing Qiao. Epidemiology of Asymptomatic Pre‑heart Failure: a Systematic Review. Current Heart Failure Reports (2022) 19:146–156. https://doi.org/10.1007/s11897-022-00542-5
XVI. Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, et al. Burden of heart failure in Flemish general practices: a registry-based study in the Intego database. BMJ Open. 2019;9(1): e022972. https:// doi. org/ 10. 1136/ bmjop en- 2018- 022972.
XVII. Gupta S, Rohatgi A, Ayers CR, Patel PC, Matulevicius SA, Peshock RM, et al. Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. Am Heart J. 2011;161(5):923–302. https:// doi. org/ 10. 1016/j. ahj. 2011. 01. 007
XVIII. Paul Welsh, Ross T. Campbell, Leanne Mooney, et al. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort. Circulation: Heart Failure. 2022; 15(10): e009427. doi: 10.1161/CIRCHEARTFAILURE.121.009427.
XIX. Gaborit FS, Kistorp C, Kumler T, Hassager C, Tonder N, Kober L, et al. Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study. Open Heart. 2019;6(1): e000840.
XX. Miguel Rivera, Raquel Taléns-Visconti, Antonio Salvador, et al. NT-proBNP Levels and Hypertension. Their Importance in the Diagnosis of Heart Failure. Rev Esp Cardiol. 2004;57(5):396-402.
XXI. Gary Tackling; Mahesh B. Borhade. Hypertensive Heart Disease. StatPearls [Internet]. 2022.
XXII. Bolortuul Byambatsogt, Bayasgalan Tumenbayar, Ganbat Mijidsuren, et al. Association between NT- pro BNP and Cardio-metabolic Risk Factors in Mongolians. International Journal of Clinical Science and Medical Research. 2021;1(1):11-17. Avaliable at: https://journalofmedical.org.
XXIII. Atsushi Tanaka, Hisako Yoshida, Atsushi Kawaguchi et al. N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study. Sci Rep. 2017; 7: 5810. doi:10.1038/s41598-017-06090-6.
XXIV. Ji-Hung Wang, Chung-Jen Lee, Jen-Che Hsieh et al. N-terminal pro-B-type natriuretic peptide level inversely associates with metabolic syndrome in elderly persons. Diabetology &Metabolic Syndrome. 2014;6:15. http://www.dmsjournal.com/content/6/1/15.
XXV. Shoko Aoki, Kazumasa Yamagishi, Tomomi Kihara, Mari Tanaka, et al. Risk factors for pre-heart failure or symptomatic heart failure based on NT-proBNP. ESC Heart Fail. 2023;10(1):90-99. doi: 10.1002/ehf2.14149.
XXVI. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12) :e154-235. https:// doi. org/ 10. 1161/ CIRCU LATIO NAHA. 105. 167586.
XXVII. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933–89.